HMGB1 and hematologic disorder: HMGB1 has transcended its traditional role as a molecular biomarker, forming a complete translational medicine framework encompassing “risk prediction‐early diagnosis‐therapeutic intervention‐combination potentiation.” Future prospective clinical trials validating the efficacy and safety of its targeted inhibitors in solid tumors and hematological malignancies are expected to provide new, rapidly implementable treatment paradigms for precision oncology.